Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition
Evan S. Dubose(University of North Carolina at Chapel Hill), Steven P. Angus(University of North Carolina at Chapel Hill)
Cited by 7
Related Papers
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
|npj Breast Cancer|2021|24